Loading
A phase 3 trial of Docetaxel in non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06012435 by Seagen, a wholly owned subsidiary of Pfizer, with 762 participants enrolled, started 2024-02-21 and due to reach its primary completion in 2026-05-18. Interventions recorded: sigvotatug vedotin and docetaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/